- Home
- CHRS vs ANEB Comparison
CHRS vs ANEB Comparison
Compare CHRS & ANEB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- ANEB
- Stock Information
- Founded
- CHRS 2010
- ANEB 2020
- Country
- CHRS United States
- ANEB United States
- Employees
- CHRS N/A
- ANEB N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- ANEB Biotechnology: Pharmaceutical Preparations
- Sector
- CHRS Health Care
- ANEB Health Care
- Exchange
- CHRS Nasdaq
- ANEB Nasdaq
- Market Cap
- CHRS 102.0M
- ANEB 117.1M
- IPO Year
- CHRS 2014
- ANEB 2021
- Fundamental
- Price
- CHRS $1.05
- ANEB $2.50
- Analyst Decision
- CHRS Buy
- ANEB Buy
- Analyst Count
- CHRS 3
- ANEB 2
- Target Price
- CHRS $4.68
- ANEB $8.00
- AVG Volume (30 Days)
- CHRS 1.5M
- ANEB 1.2M
- Earning Date
- CHRS 08-07-2025
- ANEB 09-24-2025
- Dividend Yield
- CHRS N/A
- ANEB N/A
- EPS Growth
- CHRS N/A
- ANEB N/A
- EPS
- CHRS 1.55
- ANEB N/A
- Revenue
- CHRS $272,209,000.00
- ANEB N/A
- Revenue This Year
- CHRS N/A
- ANEB N/A
- Revenue Next Year
- CHRS $142.61
- ANEB N/A
- P/E Ratio
- CHRS $2.05
- ANEB N/A
- Revenue Growth
- CHRS 52.33
- ANEB N/A
- 52 Week Low
- CHRS $0.66
- ANEB $0.80
- 52 Week High
- CHRS $2.43
- ANEB $3.42
- Technical
- Relative Strength Index (RSI)
- CHRS 62.88
- ANEB 55.36
- Support Level
- CHRS $0.81
- ANEB $2.22
- Resistance Level
- CHRS $0.95
- ANEB $2.66
- Average True Range (ATR)
- CHRS 0.07
- ANEB 0.20
- MACD
- CHRS 0.01
- ANEB -0.08
- Stochastic Oscillator
- CHRS 85.71
- ANEB 28.78
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.
About ANEB Anebulo Pharmaceuticals Inc.
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company, developing novel solutions for people suffering from cannabinoid overdose and substance addiction. The product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within 1 hour of administration. The signs and symptoms of cannabinoid overdose range from profound sedation to anxiety and panic to psychosis with hallucinations.